Treatment with Tafinlar in combination with Mekinist showed what researchers described as “considerable efficacy” among ...

Novartis’ MEK/BRAF inhibitor duo Mekinist (trametinib) and Tafinlar (dabrafenib) is now the main competitor to the two drugs, however, growing 31% to $1.12 billion in sales last year.

The drugs include Tafinlar and Mekinist, two metastatic melanoma treatments, which have recently shown promise in combination with each other. Other drugs in the portfolio include Votrient ...